These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30043425)

  • 81. Frequency and Severity of Neutropenia Associated with Food and Drug Administration Approved and Compounded Formulations of Lomustine in Dogs with Cancer.
    Burton JH; Stanley SD; Knych HK; Rodriguez CO; Skorupski KA; Rebhun RB
    J Vet Intern Med; 2016; 30(1):242-6. PubMed ID: 26682700
    [TBL] [Abstract][Full Text] [Related]  

  • 82. A retrospective study of chemotherapeutic effect without wide-margin surgery or radiation therapy in dogs with oral malignant melanoma.
    Xia Y; Liao AT; Lee J
    Can Vet J; 2024 Apr; 65(4):343-350. PubMed ID: 38562982
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Evaluation of carboplatin sustained-release delivery system in dogs with cancer.
    Tansey Baldwin C; Zwahlen CH; Kirschner S; Nakamura RK
    Vet Med Sci; 2016 Aug; 2(3):147-153. PubMed ID: 29067189
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Retrospective evaluation of toceranib phosphate (Palladia) in the treatment of canine carcinomatosis and mesothelioma.
    Hicks KA; Leeper HJ; Curran KM
    Vet Comp Oncol; 2024 Jun; 22(2):245-254. PubMed ID: 38622074
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Management of fluorouracil toxicity in a Labrador retriever-poodle crossbred dog.
    Ellis H
    Can Vet J; 2022 Jan; 63(1):81-84. PubMed ID: 34975172
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A phase II trial of carboplatin in patients with advanced APUD tumors.
    Saltz L; Lauwers G; Wiseberg J; Kelsen D
    Cancer; 1993 Jul; 72(2):619-22. PubMed ID: 8391382
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The use of lithium carbonate to prevent lomustine-induced myelosuppression in dogs: a pilot study.
    Abrams-Ogg AC
    Can J Vet Res; 2011 Jan; 75(1):73-6. PubMed ID: 21461200
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Neutropenia in dogs receiving vincristine for treatment of presumptive immune-mediated thrombocytopenia.
    LaQuaglia KA; Robertson JB; Lunn KF
    J Vet Intern Med; 2021 Jan; 35(1):226-233. PubMed ID: 33421218
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Plasma Cytokeratin 18 and fecal Alpha-1 Antitrypsin concentrations in dogs with osteosarcoma receiving carboplatin chemotherapy.
    Taikowski K; Rudinsky AJ; Louke DS; Warry E; Fenger JM
    Vet Med Sci; 2021 Mar; 7(2):385-392. PubMed ID: 33222415
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Combination therapy with cannabidiol and chemotherapeutics in canine urothelial carcinoma cells.
    Inkol JM; Hocker SE; Mutsaers AJ
    PLoS One; 2021; 16(8):e0255591. PubMed ID: 34352013
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Large granular lymphocyte lymphoma in 65 dogs (2005-2023).
    Yale AD; Crawford AL; Gramer I; Guillén A; Desmas I; Holmes EJ
    Vet Comp Oncol; 2024 Mar; 22(1):115-124. PubMed ID: 38156420
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Presumed primary immune-mediated neutropenia in 35 dogs: a retrospective study.
    Devine L; Armstrong PJ; Whittemore JC; Sharkey L; Bailiff N; Huang A; Rishniw M
    J Small Anim Pract; 2017 Jun; 58(6):307-313. PubMed ID: 28245056
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Correlation Between Body Weight and Mitoxantrone-Associated Neutropenia in Dogs.
    Richardson D; Poirier VJ; Matsuyama A; Calvalido J
    J Am Anim Hosp Assoc; 2018; 54(3):144-149. PubMed ID: 29558218
    [TBL] [Abstract][Full Text] [Related]  

  • 94. A pilot study of chemotherapy combinations in rats: Focus on mammary cancer treatment in female dogs.
    Silva LP; Yamamoto PA; Machado MCA; Neves FMF; Azeredo FJ; Dos Santos Silva ACS; Hlavac N; de Melo Soares D; Godoy ALPC; Estrela-Lima A
    Res Vet Sci; 2023 Mar; 156():14-21. PubMed ID: 36738520
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Biodynamic signatures from ex vivo bone marrow aspirates are associated with chemotherapy-induced neutropenia in cancer-bearing dogs.
    Marcum BA; Li Z; Turek JJ; Moore GE; Nolte DD; Childress MO
    Vet Med Sci; 2021 May; 7(3):665-673. PubMed ID: 33369129
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Survival time of dogs with inflammatory mammary cancer treated with palliative therapy alone or palliative therapy plus chemotherapy.
    Clemente M; De Andrés PJ; Peña L; Pérez-Alenza MD
    Vet Rec; 2009 Jul; 165(3):78-81. PubMed ID: 19617612
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Dogs as a Model for Cancer.
    Gardner HL; Fenger JM; London CA
    Annu Rev Anim Biosci; 2016; 4():199-222. PubMed ID: 26566160
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Are severe adverse events commonly observed in dogs during cancer chemotherapy? A retrospective study on 155 dogs.
    Chavalle T; Chamel G; Denoeux P; Lajoinie M; Sayag D; Berny P; Ponce F
    Vet Comp Oncol; 2022 Jun; 20(2):393-403. PubMed ID: 34775666
    [TBL] [Abstract][Full Text] [Related]  

  • 99. A Retrospective Evaluation of Chemotherapy Overdoses in Dogs and Cats.
    Musser ML; Curran KM; Flesner BK; Johannes CM
    Front Vet Sci; 2021; 8():718967. PubMed ID: 34631850
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Intensive Multimodal Chemotherapy in a Dog Suffering from Grade III/Stage IV Solid Mammary Carcinoma.
    Beaudu-Lange C; Lange E
    Animals (Basel); 2024 Sep; 14(17):. PubMed ID: 39272403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.